Canakinumab
Indication
Juvenile idiopathic arthritis (systemic) (NICE TA302)
NICE TA302 - Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
Black
Brand:
Ilaris®
Nice TA:
302
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
NICE is unable to make a recommendation about the use in the NHS of canakinumab for systemic juvenile idiopathic arthritis because no evidence submission was received from the manufacturer of the technology.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: